E0 ConsensusModerate confidencePEM not requiredReview-NarrativePeer-reviewedReviewed
Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?
Van Houdenhove, Boudewijn, Pae, Chi-Un, Luyten, Patrick · Expert opinion on pharmacotherapy · 2010 · DOI
Quick Summary
This review examined whether medications can help ME/CFS patients. Researchers looked at studies from 1988 to 2009 and found that while some drugs (like antivirals and antibiotics) might temporarily help symptoms, they can also cause more harm than good. A few stimulant medications helped some patients, but the long-term safety is unclear. The authors concluded that medications alone are not the best first-line treatment and work best alongside self-management and rehabilitation.
Why It Matters
This review is important because ME/CFS patients often seek pharmacological options but have limited evidence-based guidance. By systematically evaluating decades of drug trial data, it clarifies which medications have the most promise, which carry risks, and emphasizes that medication should be combined with self-management strategies—helping both patients and clinicians make informed treatment decisions.
Observed Findings
- Antiviral, immunological, and antibiotic therapies showed symptom amelioration in some cases but carried significant potential for harm.
- Stimulants provided benefit to some ME/CFS patients, but long-term safety and efficacy remain uncertain.
- Antidepressants did not cure ME/CFS but may help manage co-morbid anxiety and depression and certain symptoms.
- Steroids and dietary supplements showed little or no evidence of benefit in ME/CFS.
- Most pharmacological trials had heterogeneous designs and may not have used consistent ME/CFS case definitions.
Inferred Conclusions
- Pharmacotherapy cannot currently be considered first-line treatment for ME/CFS and should always be integrated with self-management and rehabilitation.
- Future drug research must account for distinct ME/CFS subgroups rather than treating the condition as homogeneous.
- Future treatment research should target immunological aspects of ME/CFS and clarify relationships between the illness, stress, and depression.
Remaining Questions
- What are the optimal long-term safety and efficacy profiles of stimulant medications in ME/CFS subgroups?
- Which immunological mechanisms in ME/CFS could be targeted by novel pharmacotherapies?
What This Study Does Not Prove
This review does not establish what causes ME/CFS or prove that any single medication is curative. It does not provide evidence that future novel pharmacotherapies targeting immune mechanisms will be effective, nor does it prove that self-management and rehabilitation alone are sufficient for all patients without adjunctive support.
Tags
Symptom:Post-Exertional MalaiseCognitive DysfunctionPainFatigue
Method Flag:Weak Case Definition
Metadata
- DOI
- 10.1517/14656560903487744
- PMID
- 20088743
- Review status
- Editor reviewed
- Evidence level
- Higher-level evidence type — systematic reviews, meta-analyses, guidelines, or major syntheses (study type, not a quality guarantee)
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.